Vir Biotechnology (NYSE:VIR) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Vir Biotechnology (NYSE:VIR) announced its quarterly earnings results on Sunday. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.07), MarketWatch Earnings reports.

VIR opened at $26.98 on Monday. Vir Biotechnology has a 1 year low of $11.65 and a 1 year high of $75.00. The stock’s 50 day simple moving average is $35.34 and its 200-day simple moving average is $38.51.

In other news, insider Jay Parrish sold 6,945 shares of the company’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $34.75, for a total transaction of $241,338.75. Following the transaction, the insider now owns 226,852 shares of the company’s stock, valued at $7,883,107. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Phillip Pang sold 12,500 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $32.89, for a total value of $411,125.00. Following the completion of the sale, the insider now owns 42,277 shares of the company’s stock, valued at approximately $1,390,490.53. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 104,774 shares of company stock worth $3,911,409.

Several brokerages have recently issued reports on VIR. Barclays lifted their price target on Vir Biotechnology from $44.00 to $61.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Zacks Investment Research lowered Vir Biotechnology from a “buy” rating to a “hold” rating in a report on Friday. JPMorgan Chase & Co. upgraded Vir Biotechnology from an “underweight” rating to a “neutral” rating and reduced their target price for the stock from $30.00 to $29.00 in a report on Friday, September 11th. The Goldman Sachs Group raised Vir Biotechnology from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $48.00 to $54.00 in a research report on Monday, September 14th. Finally, HC Wainwright lifted their price target on Vir Biotechnology from $80.00 to $100.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $52.00.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis.

See Also: Does the Dogs of the Dow strategy work?

Earnings History for Vir Biotechnology (NYSE:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.